

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION N	NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/622,182		07/16/2003	Jeffrey Van Ness	780068.416D1	9315
500	7590	11/01/2006		EXAMINER	
		CTUAL PROPERTY	RILEY, JEZIA		
701 FIFTH AVE SUITE 5400			ART UNIT	PAPER NUMBER	
SEATTL	SEATTLE, WA 98104			1637	
				DATE MAILED: 11/01/2006	6

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
Office Action Summani	10/622,182	VAN NESS ET AL.					
Office Action Summary	Examiner	Art Unit					
	Jezia Riley	1637					
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address					
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DATE - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period value - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	I. lety filed the mailing date of this communication. O (35 U.S.C. § 133).					
Status							
1) Responsive to communication(s) filed on 21 Au	iaust 2006.						
	- ''						
<u> </u>	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under E	•						
Disposition of Claims							
4)⊠ Claim(s) <u>59-86</u> is/are pending in the application.							
	4a) Of the above claim(s) <u>83-85</u> is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.							
6)⊠ Claim(s) <u>59-67</u> is/are rejected.	· · · ——						
7)⊠ Claim(s) <u>68-82 and 86</u> is/are objected to.							
8) Claim(s) <u>59-86</u> are subject to restriction and/or	election requirement.						
Application Papers							
9)☐ The specification is objected to by the Examine	_						
		Evaminar					
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11) The oath or declaration is objected to by the Ex							
The bath of declaration is objected to by the Ex	ammer. Note the attached Office	Action or form PTO-152.					
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau * See the attached detailed Office action for a list	s have been received. s have been received in Application ity documents have been received (PCT Rule 17.2(a)).	on No ed in this National Stage					
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 1/256/34	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	te					

Art Unit: 1637

DETAILED ACTION

Election/Restrictions

1. Applicant's election with traverse of the following species (1) the L group as shown in claim 77, wherein R1 is H; and (2) the Tms group as shown in claim 83, wherein T2 is ethoxyacetic acid (see, claim 86); T4 is ethoxybenzene; c is 1 (see, claim 83); G is CH (see, claim 83); m is 1 (see, claim 83); R1 is H (see claim 83); and Ts is 1-methypiperidine-4-carbaldehyde (see, claim 84), is acknowledged. However, no prior art was found, therefore all species were examined and the requirement withdrawn.

Claim Objections

2. Claims 83-84 are objected to under 37 CFR 1.75(c) as being in improper form because a multiple dependent claim should refer to other claims in the alternative only. Claim 83 refers to claim 68 and claim 1. See MPEP § 608.01(n). Accordingly, the claims 83-85 have not been further treated on the merits.

Double Patenting

3. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422

Art Unit: 1637

F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

4. Claims 59-67 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-5, 8, 11-13 of U.S. Patent No. 6,312,893. Although the conflicting claims are not identical, they are not patentably distinct from each other because they are claiming a method comprising DNA fragments having cleavably attached thereto a mass tag, separating the tagged fragments, and characterizing each tag by mass spectrometry.

Claim Rejections - 35 USC § 102

- 5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
 - (e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.
- 6. Claims 59, 60, 62 are rejected under 35 U.S.C. 102(e) as being anticipated by Southern et al. (US 6,576,426 B2).

Southern et al. discloses a reagent comprising a) an analyte moiety comprising at least two analyte residues, and linked to b) a tag moiety comprising one or more reporter

Application/Control Number: 10/622,182

Art Unit: 1637

groups suitable for detection by mass spectrometry, excluding oligonucleotides, wherein a reporter group designates an analyte residue, and the reporter group at each position of the tag moiety is chosen to designate an analyte residue at a defined position of the analyte moiety. Preferably the analyte moiety is linked to the tag moiety by a link which is cleavable, e.g. photocleavable. There may be provided a linker group to which the analyte moiety and the tag moiety are both attached. Preferably the analyte moiety is a chain of n analyte residues, and the tag moiety is a chain of up to n reporter groups, the reporter group at each position of the tag chain being chosen to designate the analyte residue at a corresponding position of the analyte chain. n is an integer of at least 2,

Page 4

7. Claims 68-82 and 86 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

preferably 3 to 20. See summary of the invention and Figures 2-5.

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jezia Riley whose telephone number is 571-272-0786. The examiner can normally be reached on 9:30AM - 5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on 571-272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/622,182

Art Unit: 1637

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

29 October 2006

//JEZIA RILEY PRIMARY EXAMINER Page 5